Alzamend Neuro, Inc. (ALZN)
Nasdaq: ALZN · Pharmaceutical Preparations · Atlanta, GA · filing with the SEC since 2016
Who runs Alzamend Neuro, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Jackman Stephan
Chief Executive Officer. First filing Jun 2021, latest Aug 4, 2026, 2 filings in all.
Officers reporting now
3
of 11 people with a filing in the last fifteen months
Directors reporting now
8
14 people on the record since 2021
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Jackman Stephan | Chief Executive Officer | Jun 2021 | Aug 4, 2026 | none |
| Katzoff David J | Chief Financial Officer | Jun 2021 | Aug 4, 2026 | none |
| Nisser Henry Carl | EVP and General Counsel | Jun 2021 | Aug 4, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Ault Milton C III | director | Jun 2021 | Aug 31, 2026 | 10 · $1.0M |
| Ault Capital Group, Inc. | director | Aug 2026 | Aug 20, 2026 | none |
| Ault Lending, LLC | director | Aug 2026 | Aug 20, 2026 | none |
| Hyperscale Data, Inc. | director | Aug 2026 | Aug 20, 2026 | none |
| Gustafson Mark | director | Jun 2021 | Aug 4, 2026 | none |
| Horne William B. | director | Jun 2021 | Aug 4, 2026 | 1 · $0.00 |
| Oram Jeffrey | director | Jun 2021 | Aug 4, 2026 | none |
| Mcgrath Lynne Fahey | director | Jun 2021 | Oct 24, 2025 | 1 · $0.00 |
Earlier names on the record3, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.